Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens

Pietrantonio, Filippo; Perrone, Federica; Biondani, Pamela; Maggi, Claudia; Lampis, Andrea; Bertan, Claudia; Venturini, Filippo; Tondulli, Luca; Ferrari, Daris; Ricci, Vincenzo; Villa, Federica; Barone, Gloria; Bianco, Nadia; Ghidini, Antonio; Bossi, Ilaria; Fanetti, Giuseppe; Di Bartolomeo, Maria; de Braud, Filippo
December 2013
Cancer Biology & Therapy;Dec2013, Vol. 14 Issue 12, p1
Academic Journal
No abstract available.


Related Articles

  • Mutant KRAS tumor status may impair efficacy of EGFR inhibitors. Venook, Alan // Hem/Onc Today;2/25/2008, Vol. 9 Issue 3, p18 

    The article discusses a study which investigated the effect of mutant KRAS tumor status on the efficacy of EGFR inhibitors. The researchers found that the efficacy of single-agent panitumumab in patients with metastatic colorectal cancer is limited to patients with wild-type KRAS tumor status....

  • Panitumumab.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p237 

    The article discusses a retrospective study on the development of thrombocytopenia in a patient who received panitumumab for the treatment of KRAS wild-type metastatic colorectal cancer.

  • FOLFIRI plus panitumumab effective in metastatic colorectal cancer.  // Hem/Onc Today;2/10/2014, Vol. 15 Issue 3, p15 

    The article highlights the results of a study indicating that a treatment regimen consisting of FOLFIRI chemotherapy plus the prescription drug panitumumab could significantly enhance the progression-free survival (PFS) rates of metastatic colorectal cancer patients with KRAS wild-type tumors.

  • Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients. Lin, Yu-Lin; Liang, Yi-Hsin; Tsai, Jia-Huei; Liau, Jau-Yu; Liang, Jin-Tung; Lin, Been-Ren; Hung, Ji-Shiang; Lin, Liang-In; Tseng, Li-Hui; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and...

  • Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Mancl, Erin E.; Kolesar, Jill M.; Vermeulen, Lee C. // American Journal of Health-System Pharmacy;12/1/2009, Vol. 66 Issue 23, p2105 

    Purpose. The clinical and economic value of screening for Kras mutations as predictors of response to cetuximab and panitumumab are reviewed. Summary. Epidermal growth factor receptor (EGFR) inhibitors cetuximab and panitumumab are agents currently used in the treatment of metastatic colorectal...

  • Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Wadlow, Raymond C.; Hezel, Aram F.; Abrams, Thomas A.; Blaszkowsky, Lawrence S.; Fuchs, Charles S.; Kulke, Matthew H.; Kwak, Eunice L.; Meyerhardt, Jeffrey A.; Ryan, David P.; Szymonifka, Jackie; Wolpin, Brian M.; Zhu, Andrew X.; Clark, Jeffrey W. // Oncologist;Jan2012, Vol. 17 Issue 1, p14 

    An abstract of the article "Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab," by Raymond C. Wadlow and colleagues is presented.

  • Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer. Freeman, Daniel J. // Clinical Medicine: Therapeutics;2009, Issue 1, p633 

    Therapies targeting epidermal growth factor receptor (EGFR) are a promising recent development in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a fully human anti-EGFR monoclonal antibody that competitively inhibits the binding of all known EGFR ligands, including...

  • Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response-a retrospective study Yang, Yuan-Hao; Lin, Jen-Kou; Chen, Wei-Shone; Lin, Tzu-Chen; Yang, Shung-Haur; Jiang, Jeng-Kai; Lan, Yuan-Tzu; Lin, Chun-Chi; Yen, Chueh-Chuan; Tzeng, Cheng-Hwai; Teng, Hao-Wei // Journal of Cancer Research & Clinical Oncology;Nov2014, Vol. 140 Issue 11, p1927 

    Purpose: We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients with metastatic colorectal cancer. Methods: Between April 2005 and March 2012,...

  • Panitumumab: In Metastatic Colorectal Cancer with Wild-Type KRAS. Weber, Juliane; McCormack, Paul L. // BioDrugs;2008, Vol. 22 Issue 6, p403 

    Panitumumab is a fully human IgG2 monoclonal antibody that is highly selective for the epidermal growth factor receptor (EGFR), which is overexpressed in 25-77% of colorectal cancers and is often associated with a poor prognosis. Binding of panitumumab to chemotherapy regimens EGFR reduces cell...

  • KRAS status predicted panitumumab response.  // Hem/Onc Today;12/10/2008, Vol. 9 Issue 22, p37 

    The article reports on the results of four clinical studies which aimed to determine the efficacy of panitumumab monotherapy in relation to KRAS mutational status for treating metastatic colorectal cancer. Findings show that KRAS appears to be a valid biomarker for determining which patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics